We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Technique Identifies Initial Events in Tumor Development

By LabMedica International staff writers
Posted on 10 Oct 2011
Print article
A novel technique that enables scientists to measure and record tumor-inducing changes in DNA is providing new clues into the earliest events involved in the formation of leukemias, lymphomas, and sarcomas, it and could possibly lead to the discovery of ways to stop those events.

Developed by a team of researchers at the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS; Bethesda, MD, USA), and the National Cancer Institute (NCI; Bethesda, MD, USA), both parts of the National Institutes of Health, and the Rockefeller University (New York, NY, USA), the technology centers on chromosomal rearrangements known as translocations. Translocations occur when a broken strand of DNA from one chromosome is erroneously joined with that of another chromosome. Sometimes these irregularities can be beneficial in that they enable the immune system to respond to a vast number of microorganisms and viruses. However, translocations can also result in tumors.

The study’s findings were reported in the September 30, 2011, issue of the journal Cell. Translocations can take place during the course of normal cell division, when each chromosome--a single strand of DNA containing many genes--is copied verbatim to provide genetic information for the daughter cells. Occasionally, during this process, byproducts of normal metabolism or other factors can cause breaks in the DNA.

“The cell expresses specific enzymes whose primary purpose is to repair such lesions effectively, but when the enzymes mistakenly join pieces of two different chromosomes, the cell’s genetic information is changed,” said Rafael C. Casellas, PhD, senior investigator in the Genomics and Immunity Section at the NIAMS, who led the research team along with Michel C. Nussenzweig, MD, PhD, from Rockefeller University.

Scientists have known since the 1960s that recurrent translocations play a key role in cancer. What was not clear was how these genetic abnormalities are created, since very few of them were examined, and only within the context of tumors, according to Dr. Casellas. To better understand the nature of these tumor-inducing rearrangements, the authors had to create a system to visualize their appearance in normal, nontransformed cells.

The system the scientists designed involved introducing enzymes that recognize and cause damage at a particular sequence in the DNA into cells from mice, thereby constructing a genome where a unique site is broken continuously. The investigators then utilized a method called polymerase chain reaction (PCR)--which allows scientists to rapidly quickly amplify short sequences of DNA--to inspect all the sites in the genome that would get translocated to this particular break. Using this technique, they were able to explore more than 180,000 chromosomal rearrangements from 400 million white blood cells, called B cells.

Based on this large data set, the scientists were able to make several significant observations about the translocation process. They determined that most of the translocations involve gene domains, instead of the space on the DNA between the genes. They also discovered that most translocations target active genes, with a clear predisposition for the beginning of the gene, as opposed to its middle or end. The team also showed that a specific enzyme that normally creates DNA breaks in B cells dramatically increases the incidence of translocations during the immune response. This characteristic clarifies the long-standing observation that more than 95% of human lymphomas and leukemias are of B cell origin.

“This knowledge is allowing us to understand how tumors are initiated,” concluded Dr. Casellas. “It is the kind of information that in the near future, might help us prevent the development of cancer.”

Related Links:

National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Cancer Institute
National Institutes of Health, and the Rockefeller University



New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Static Concentrator
BJP 10
New
Leishmania Test
Leishmania Real Time PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.